REMD Biotherapeutics
Business Services · California, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
4010 Adolfo Rd Ste A, Camarillo, Califor...Phone Number
(805) 987-0600Website
www.remdbio.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About REMD Biotherapeutics
REMD Biotherapeutics is a privately held, clinical-stage biotechnology company focused on creating and developing innovative protein-based therapies to treat metabolic diseases and other serious illnesses. The Company was founded by two former Amgen research scientists and has facilities in Camarillo, California and Beijing, China. REMD Bio's lead product candidate, volagidemab (REMD-477), a fully human competitive antagonistic antibody to the glucagon receptor licensed from Amgen in 2013, is presently in clinical studies for treatment of diabetes as well as in preclinical studies for treatment of other metabolic disorders. REMD Bio's discovery research leverages extensive expertise in generating and developing therapeutic antibodies to G protein-coupled receptors (GPCRs) as well as to other multi-transmembrane cell surface antigens.Explore more
REMD Biotherapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is REMD Biotherapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if REMD Biotherapeutics is spiking on competitors!
Click to see if REMD Biotherapeutics had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at REMD Biotherapeutics
Product Launch: Get notified when REMD Biotherapeutics launches new products
Earning: See what the market has to say on REMD Biotherapeutics recently announced quarterly report
Website visits: Recent activity has been detected on your website
REMD Biotherapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once REMD Biotherapeutics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if REMD Biotherapeutics has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined REMD Biotherapeutics as Masked Content
Find 2 more new buyers
Compare Similar Companies to REMD Biotherapeutics
Compare insights from companies similar to REMD Biotherapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
REMD Biotherapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
REMD Biotherapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about REMD Biotherapeutics.
REMD Biotherapeutics financials insights
Gather financial insights about REMD Biotherapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$150K
REMD Biotherapeutics Tech Stack
A closer look at the technologies used by REMD Biotherapeutics
REMD Biotherapeutics News & Media
A bispecific antibody molecule jointly developed by Buchang Pharmaceutical and REMD Biotherapeutics, partners of GenScript ProBio, received IND clearance from NMPA for clinical trial
NANJING, China, Nov. 29, 2022 /PRNewswire/ -- Buchang Biopharmaceutical and REMD Biotherapeutics, partners of GenScript ProBio, recently received IND approval of BC008-1A from China NMPA for Phase 1 clinical trial. BC008-1A (NMPAIND number: CXSL2200315), a bispecific antibody drug co-targeting the immune checkpoints PD-1 and TIGIT, for treatment of patients with advanced solid tumors. GenScript ProBio extends congratulations on this. Buchang Biopharmaceutical will be responsible for the Phase 1REMD Biotherapeutics Announces Positive Top-Line Results in a Phase 2 Program of Lead Product Candidate Volagidemab in Patients with Type 1 Diabetes
CAMARILLO, Calif.--(BUSINESS WIRE)--REMD Bio announced results from a phase 2 clinical program of volagidemab in patients with type 1 diabetes were presented at #ADA2021.REMD Biotherapeutics Completes Enrollment and Announces Top-line Results of a Phase 2 Clinical Study of Volagidemab (REMD-477) in Patients with Type 1 Diabetes
CAMARILLO, Calif.--(BUSINESS WIRE)--REMD Bio completed enrollment and announced top-line results in a phase 2 clinical study of volagidemab (REMD-477) in patients with type 1 diabetes.Expanding Their Existing Strategic Collaboration, GenScript ProBio Licensed Global Rights to Develop and Commercialize a SMAB Bispecific Antibody Molecule to REMD Biotherapeutics Inc.
NANJING, China, Sept. 17, 2020 /PRNewswire/ -- On September 16th, 2020, GenScript ProBio and REMD Biotherapeutics Inc. (REMD) announced that REMD has licensed a bispecific antibody derived from the Single-domain antibody fused to Monoclonal Ab (SMAB) platform developed by GenScript ProBio....
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding REMD Biotherapeutics
Sign Up For FreeTo access detailed company insights
REMD Biotherapeutics is a privately held, clinical-stage biotechnology company focused on creating and developing innovative protein-based therapies to treat metabolic diseases and other serious illnesses. The Company was founded by two former Amgen research scientists and has facilities in Camarillo, California and Beijing, China. REMD Bio's lead... Read More
